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A B S T R A C T
The progression of aggressive cancer occurs via angiogenesis and metastasis makes these processes
important targets for the development of anti-cancer agents. However, recent studies have raised the
concern that selective inhibition of angiogenesis results in a switch towards increased tumour growth
and metastasis. Since Annexin A2 (AnxA2) is involved in both angiogenesis and metastasis, it may serve
as an ideal target for the simultaneous inhibition of both processes. Based on the discovery that domains
I (DI) and IV (DIV) of AnxA2 are potent inhibitors of angiogenesis, we designed seven peptides derived
from these domains based on AnxA2 crystal structures. The peptides were expressed as fusion peptides
to increase their folding and solubility. Light scattering, far-UV circular dichroism and thermal transition
analyses were employed to investigate their aggregation tendencies, a-helical propensity and stability,
respectively. 2,2,2-triﬂuoroethanol (50%) increased the a-helical propensities of all peptides, indicating
that they may favour a hydrophobic environment, but did not enhance their thermal stability. DI-P2
appears to be the most stable and folded peptide in a hydrophilic environment. The secondary structure
of DI-P2 was conﬁrmed by nuclear magnetic resonance spectra. The effect of the seven AnxA2 peptides
on the formation and integrity of capillary-like networks was studied in a co-culture system mimicking
many of the angiogenesis-related processes. Notably, DI-P2 inhibited signiﬁcantly network formation in
this system, indicating that the folded DI-P2 peptide interferes with vascular endothelial growth factor-
dependent pro-angiogenic processes. Thus, this peptide has the potential of being developed further as
an anti-angiogenic drug.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jo u rn al h om epag e: ww w.els evier .c o m/lo cat e/b io c hem p har m1. Introduction
Angiogenesis is a tightly coordinated process involving the
proliferation, directed migration and differentiation of cells.Abbreviations: AnxA2, Annexin A2 protein; AnxA2-DI, domain I of AnxA2; AnxA2-
DIV, domain IV of AnxA2; CD, circular dichroism; CSI, chemical shift index; ECM,
extracellular matrix; ECs, endothelial cells; FL, full-length; GFP, green ﬂuorescent
protein; HUVECs, human umbilical vein endothelial cells; MBP, maltose binding
protein; NMR, nuclear magnetic resonance; P, peptide; SMCs, pulmonary artery
smooth muscle cells; TEV, tobacco etch virus; TFE, 2,2,2-triﬂuoroethanol; tPA,
tissue plasminogen activator; VE-cadherin, vascular endothelial cadherin; VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor
receptor.
* Corresponding author at: Jonas Lies vei 91, N-5009 Bergen, Norway.
Tel.: +47 55586435; fax: +47 55586360.
E-mail address: Anni.Vedeler@biomed.uib.no (A. Vedeler).
http://dx.doi.org/10.1016/j.bcp.2015.02.013
0006-2952/ 2015 The Authors. Published by Elsevier Inc. This is an open access article unAdditionally, cell–cell communication is highly essential, when
new blood vessels form from an established vascular network
[1,2]. A multitude of proteins, including growth factors and
cytokines, regulate angiogenesis, with members of the vascular
endothelial growth factor (VEGF) family acting as the main
orchestrators [1,3,4]. During angiogenic growth, endothelial cells
(ECs) present in the blood vessel wall are selected for sprouting by
extracellular factors. The selected tip cells establish the growing
sprout, while sprouting of neighbouring ECs is repressed. The
surrounding ECs constituting the stalk of the new vessel sprout,
actively divide to move the tip cells forward [1]. A prerequisite for
migration is degradation of the extracellular matrix (ECM) in front of
the tip cells. ECM breakdown is carried out by proteases, including
plasminogen activators, which also indirectly enhance EC sprouting
by releasing matrix-bound angiogenic activators, such as basic
ﬁbroblast growth factor, VEGF, transforming growth factor and byder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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regulated balance of these factors in the ECM is crucial for the
remodelling processes taking place during angiogenesis. Thus,
insufﬁcient ECM degradation will prevent vascular cells from
leaving their original position, whereas excessive breakdown will
remove critical support and guidance for migrating ECs and
consequently inhibit angiogenesis [5]. In contrast to physiological
angiogenesis, during tumour angiogenesis the balance of pro- and
anti-angiogenic signals is completely deregulated, since the tumour
itself secretes pro-angiogenic signals [5,6]. Tumour angiogenesis is
critically important for the growth of solid tumours and is
considered as one of the hallmarks of cancer [7,8]. It is recognised
as an ideal therapeutic target, since most blood vessels are quiescent
in adults [9], thus decreasing the probability of unwanted side-
effects.
Annexin A2 (AnxA2) is a member of the ubiquitous Annexin
protein family and is present in several intracellular compartments
including the nucleus. However, it is also found extracellularly,
associating with the ECM of certain cell types, such as ECs [10–13]. It
is a multifunctional protein which binds to diverse intracellular
ligands such as Ca2+, S100A10 [10], membrane lipids [10–12], actin
[14–16] and speciﬁc mRNAs [17,18]. Ligand binding, and thus the
function of AnxA2, is regulated by its post-translational modiﬁca-
tions. Extracellular AnxA2 acts as a co-receptor for tissue
plasminogen activator (tPA) and plasminogen, resulting in increased
local plasmin generation [19]. Interestingly, at cell–cell contact sites
of conﬂuent human umbilical vein endothelial cells (HUVECs),
AnxA2 in complex with S100A10 is also found in conjunction with
vascular endothelial (VE)-cadherin associating with cholesterol
rafts. AnxA2 docks the VE-cadherin based complex to the actin
cytoskeleton, providing mechanical strength to the adherens
junctions [20]. Conversely, VEGF uncouples the AnxA2-S100A10
complex from the VE-cadherin based junction [20]. Moreover,
phosphorylation of VE-cadherin is associated with weak junctions
and impaired barrier function [21], which is increased in AnxA2-
depleted ECs, emphasising a role for AnxA2 in the junction complex
[22]. AnxA2 has been suggested to regulate endothelial morpho-
genesis via an adherens junction-mediated pathway upstream of
Akt [22]. It also interacts with carcino-embryonic antigen cell
adhesion molecule-1 (CEACAM1) [23], which is an extracellular
transmembrane glycoprotein found at cell-cell contact sites of
certain cell types, including activated ECs that participate in
angiogenesis [24]. Furthermore, both proteins of the AnxA2-
S100A10 complex [25,26] interact with the cell-cell adhesion
molecule AHNAK [27], mediating its translocation from the cytosol
to the inner surface of the plasma membrane, particularly in ECs
forming speciﬁc blood-tissue barriers [28]. This indicates a complex
role of AnxA2 in cell–cell adhesion. We have previously shown that
domains I and IV of AnxA2 inhibit the formation of a vascular-like
network in a co-culture system of HUVECs and smooth muscle cells
(SMCs). In addition, these domains are able to disrupt a pre-formed
network by interfering with VE-cadherin-mediated adhesion
between the ECs [29].
Structurally, AnxA2 is a typical Annexin [30]. The unique 3 kDa
N-terminal tail of AnxA2 consists of 33 amino acid residues and
folds into a structurally separate unit [31]. The convex surface of
the tightly packed a-helical protein core structure contains the
Annexin repeats, which are involved in the Ca2+-dependent
association of AnxA2 with membranes [10]. Both termini are
present on the concave side of AnxA2 and are accessible for further
interactions. The core structure of AnxA2 contains four domains,
each composed of ﬁve a-helices (A-E) connected by short loops or
turns [32]. Helices A and B as well as helices D-E are arranged in an
approximately antiparallel manner in the full-length structure
with helix C oriented almost perpendicular to the two pairs of
helices [32]. We have been able to purify a soluble and partiallyfolded form of AnxA2 domain IV by mutating hydrophobic amino
acids involved in interfacial contacts with the other domains
[33]. This domain as well as the soluble and fully folded domain I of
AnxA2 showed potent anti-angiogenic effects when tested in the
co-culture system [29].
Peptides are regarded as promising candidates in the develop-
ment of novel drugs against a range of diseases. Several peptides
are currently in therapeutic use, including peptide antibiotics such
as the polymyxins and peptides derived from insulin and
recombinant erythropoietin (EPO) for the treatment of diabetes,
and anaemic and chronic renal failure patients, respectively
[34]. The advantages of peptides over whole proteins or domains
include high speciﬁcity and activity, fewer unspeciﬁc molecular
targets, minimisation of drug–drug interactions and lack of
immune responses in the host cell. Disadvantages include low
bioavailability for oral administration, lower stability and immu-
nogenic effects [35]. In the present study, seven peptides based on
the amino acid sequence of domains I and IV of AnxA2 were
designed, expressed as maltose binding protein (MBP)-fusion
peptides and characterised for aggregation and secondary struc-
ture using light scattering assays and far-UV circular dichroism
(CD) measurements, respectively, followed by functional testing
for anti-angiogenic effects in the co-culture system.
2. Materials and methods
2.1. Protein puriﬁcation
The expression and puriﬁcation of the AnxA2 peptides as fusion
peptides coupled to His-MBP were performed as described for
AnxA2-DI [29] and AnxA2-DIV [33]. The primers used for the creation
of the cDNAs encoding the peptides are listed in Table 1. Brieﬂy, the
fusion peptides were puriﬁed on His-Select Ni2+-afﬁnity resin
(Sigma–Aldrich Co.; St. Louis, MO, USA), followed by elution of the
His-tagged peptides and immediate loading on a PD-10 column
(Sephadex G-25; GE Healthcare; Norway) equilibrated with the
tobacco etch virus (TEV) cleavage/storage buffer (20 mM Tris, pH 8)
(Sigma–Aldrich Co.; St. Louis, MO, USA). His-TEV protease cleaved
peptides were separated from His-MBP, His-TEV and the uncleaved
fusion peptides by a subsequent puriﬁcation on His-Select Ni2+-
afﬁnity resin (Sigma–Aldrich Co.; St. Louis, MO, USA), since the
peptides do not bind to this resin.
2.2. Protein concentration determination
The concentration of His-MBP fusion peptides was determined
using the Bradford method [36], while the concentration of the
puriﬁed peptides was measured using the ‘‘Direct Detect’’ infrared
spectroscopy quantitation system (Merck Millipore, Darmstadt,
Germany), which takes advantage of the fact that proteins
naturally vibrate due to stretching and bending of certain chemical
groups along the polypeptide backbone and can absorb energy in
the infrared region (www.millipore.com).
2.3. Light scattering assay
To study the aggregation tendencies of both the MBP-fusion
peptides and the cleaved peptides, in vitro light scattering assays
were performed [37]. Prior to light scattering assays, the His-MBP-
fusion peptides in 20 mM Tris (pH 8) (Sigma–Aldrich Co.; St. Louis,
MO, USA) were centrifuged for 30 min at 16000  g at 4 8C to
remove pre-formed aggregates. Assays (120 ml) were performed at
4 8C for 1 h with only the fusion peptide (1 mg/ml) in the cuvette,
followed by addition of TEV protease (1:50 molar ratio) and further
incubation for another 2 h. The aggregation rate of the fusion
peptide/TEV-cleaved peptide was followed in real-time by light
Table 1
AnxA2 peptides Direction Sequence
DI-P1 Forward 50-atccgggaagactc-catggggtcagtcaaagcgtacactaac-30
Reverse 50-atccgggaagactg-gtacctcagctgcggttggtcaggatgtt-30
DI-P2 Forward 50-atccgggaagactc-catgaagaaggaacttgcatcagcac-30
Reverse 50-atccgggaagactg-gtaccctatgttttcaataggcccaaaatcactg-30
DIV-P1 Forward 50-atccgggaagactt-catgggtcagaacaagcccctgtattttgct-30
Reverse 50-atccgggaagactg-gtacctcagtccacttcactgcgcgagacc-30
DIV-P2 Forward 50-gtcac-catgggcaagtccctgtactacta-30
Reverse 50-atccgggaagactg-gtacctcagtcatccccaccacacagg-30
DIV-P3 Forward 50-atccgggaagactt-catgggtagaacaagcccctgtcttatgctgacagactgtatgactcc-30
Reverse 50-atccgggaagactg-gtacctcagtccgattcactgcgcgagctc-30
DIV-P4 Forward 50-atccgggaagactc-catgggcaagtccctgtactactatattcag-30
Reverse 50-atccgggaagactg-gtacctcagtcatccccaccacacagg-30
DIV-P5 Forward 50-atccgggaagactc-catggaagtggacatgttgaaaat-30
Reverse 50-atccgggaagactg-gtacctcagtcatccccaccacacagg-30
The underlined gaagac sequence refers to the BbsI restriction enzyme recognition site to introduce NcoI and Acc65I compatible sites (indicated in bold) at the 50
and 30 ends, respectively. The BbsI cleavage sites are indicated by hyphens. The DI-P2 and DIV-P3 have lost their NcoI sites due to codon usage to specify speciﬁc
amino acids. All primers were supplied by Sigma.
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350 nm using an Agilent 8453 Diode Array Spectrophotometer
with a Peltier temperature control unit.
2.4. Circular dichroism (CD)
Peptides (50–170 mM) were prepared in either 20 mM Tris (pH
8) or a 50% mixture of 2,2,2-triﬂuoroethanol (TFE) (Sigma–Aldrich
Co.; St. Louis, MO) and 20 mM Tris (pH 8) to mimic behaviour in a
hydrophobic environment. The far-UV CD spectra (185–260 nm,
light path 1 mm) of the peptides were recorded at 20 8C in a Jasco J-
810 spectropolarimeter equipped with a Peltier temperature
control unit. The spectra obtained were the average of 4 scans.
Buffer scans were subtracted from the peptide spectra. Due to the
UV absorption of the Tris buffer components at short wavelengths
the spectra shown in the Figures are cut at 195 nm to be in a
reliable range. Thermal transition curves (10–70 8C) were deter-
mined by monitoring the decrease in ellipticity at 222 nm at a
scanning rate of 40 8C/h using a 1 mm path length cuvette.
2.5. Puriﬁcation and crystallisation of bovine AnxA2
Bovine full-length wt AnxA2 was expressed in the BL21 strain of
E. coli as a recombinant MBP fusion protein from cDNA present inTable 2
Crystallographic analysis of bovine AnxA2.
Data collection
Space group P212121
Unit cell (A˚/8) a = 48.3, b = 63.3, c = 117.3, a = b = g = 90.0
Resolution (A˚)a 50.00–2.01 (2.08–2.01)
Rmerge
a 0.048 (0.276)
I/s(I)a 37.6 (5.9)
No. of unique reﬂections 23260
Redundancya 6.9 (6.4)
Completeness (%)a 99.7 (99.1)
Reﬁnement
Rwork/Rfree (%) 15.7/20.9
No. atoms
Protein 2540
Ligand/Ion 4
Water 267
Mean B-factors (A˚2)
Protein 38
Ligand/Ion 54
Water 45
R.m.s. deviations
bond length (A˚) 0.017
bond angle (8) 1.8
PDB code 4X9P
a Data for the highest resolution shell are shown in parentheses.the pETM-41 vector (a kind gift from Gunter Stier, EMBL,
Heidelberg) and cleaved from MBP during puriﬁcation by TEV
protease essentially as described [33]. The bovine AnxA2 crystals
were grown at room temperature by the hanging drop method. The
reservoir buffer contained 30% PEG 4000, 0.1 M Na acetate pH 4.6,
0.2 M ammonium acetate (Hampton Research, CA, USA). The drop
consisted of 0.5 ml protein solution with the concentration of
2.3 mg/ml and 0.5 ml reservoir buffer supplemented with 20 mM
CaCl2 and 1 mM MgCl2 (Sigma–Aldrich Co.; St. Louis, MO, USA). The
bipyramidal crystals were formed within a week. The crystals
belonged to the space group P212121 with unit cell parameters
a = 48.3 A˚, b = 63.3 A˚ and c = 117.3 A˚ and a single subunit of AnxA2
in the asymmetric unit.
X-ray diffraction data were collected from the crystal ﬂash
cooled with liquid N2 and maintained at 100 K at the 19-BM
beamline at Argonne National Laboratory. HKL-3000 [38] was used
for the crystallographic data collection and processing, structure
solution, and reﬁnement. The structure of bovine AnxA2 was
solved by molecular replacement using the structure of human
AnxA2 (PDB: 1XJL) as a model. No electron density was observed
for the N-terminal segment that included four extra residues
resulting from the TEV cleavage site and ﬁrst 21 residues of AnxA2.
The structure was reﬁned to R/Rfree = 15.7%/20.9% at 2.0 A˚
resolution. Data collection and reﬁnement statistics are presentedFig. 1. 2D 1H TOCSY spectrum (grey) over layered with 2D 1H NOESY spectrum
(black). Black signals without grey signals mainly indicate NH/NH(i,i+1) cross peaks
and show that DI-P2 contains secondary structure.
A.M. Raddum et al. / Biochemical Pharmacology 95 (2015) 1–154in Table 2. The coordinates and structure factors are deposited in
the Protein Data Bank with accession code 4X9P.
2.6. Solid-phase peptide synthesis
The stepwise solid-phase synthesis of the peptide amide DI-P2
was performed on an automated ABI 433A peptide synthesizer
from Applied Biosystems on a 0.1 mM scale, using conventional
Fmoc/tBu strategy (N,N,N0,N0-Tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexaﬂuorophosphate (HBTU), N,N-Diisopropylethyla-
mine (DIEA), Nmethylpyrrolidone (NMP) (Sigma–Aldrich Co.; St.
Louis, MO, USA)). As solid support preloaded H-Rink Amide-
ChemMatrix resin (100 mg, loading 0.52 mmol/g) from PCAS
BioMatrix Inc. was used. All amino acids were coupled according
to standard methodologies in an automated single mode. Fmoc
deprotection was carried out with 20% piperidine (Sigma–Aldrich
Co.; St. Louis, MO, USA) in NMP. Cleavage of crude peptides
from the resin was accomplished through treatment with 95%Fig. 2. Schematic presentation of the seven different AnxA2 peptides in the context of the
structure of FL AnxA2 (B). (A): Two peptides derived from each of wt AnxA2 domains I
mutated domain IV (DIV-P3, DIV-P4 and DIV-P5) are indicated by solid lines above the li
amino acid sequences. The mutations introduced into AnxA2-DIV to render it more solu
structure of bovine AnxA2 (Protein data bank (PDB) code: 4X9P). The colour code of the r
E96 in helix E in AnxA2-DI are underlined.Triﬂuoroacetic acid (TFA) (Sigma–Aldrich Co.; St. Louis, MO, USA)
2.5% water, 2.5% Triisopropylsilane (TIPS) (Sigma–Aldrich Co.; St.
Louis, MO, USA) for 1.5 h. Preparative puriﬁcation by high-pressure
liquid chromatography (HPLC) was carried out on a Shimadzu LC-
8A system with a Sepserv ES (250  21.2 mm) column (Buffer A:
0.2% TFA in water, Buffer B: 0.2% TFA in water: acetonitrile, 1:4)
(Sigma–Aldrich Co.; St. Louis, MO, USA). The puriﬁed peptides were
dried by lyophilisation and characterised by analytical HPLC and
mass spectral analysis [39].
2.7. NMR spectroscopy
Prior to NMR analysis of DI-P2, the peptide was dissolved in
600 ml 50 mM aqueous phosphate buffer pH 7.0 containing 10%
D2O (v/v) (Sigma–Aldrich Co.; St. Louis, MO, USA) and transferred
to a Wilmad 528-PP-7 NMR tube. TFE-D2O was delivered by
Cambridge Isotope Laboratories, Inc. (MA, USA). The 1D and 2D 1H
NMR experiments (Total Correlation Spectroscopy (TOCSY) and bovine amino acid sequences of wt DI, wt DIV or mutated DIV (A) and 3 dimensional
 (DI-P1 and DI-P2) and IV (DIV-P1 and DIV-P2) and three peptides derived from the
near amino acid sequences. The a-helices (A-E) are indicated by barrels below the
ble are indicated in red letters. (B): The structure of AnxA2 is based on the crystal
espective peptide amino acid sequences in (A) is also used in (B). K88 in helix D and
Fig. 3. Gel analysis of puriﬁed His-MBP-AnxA2 fusion peptides (A) and TEV-cleaved
AnxA2 peptides (B). (A): 10 mg of the Ni2+-afﬁnity puriﬁed His-MBP-AnxA2
peptides DI-P1, DI-P2, DIV-P1, DIV-P2, DIV-P3, DIV-P4 and DIV-P5 (lanes 2-8,
respectively, as indicated), were analysed by 15% SDS-PAGE. (B): 10 mg of the
puriﬁed TEV protease-digested AnxA2 peptides DI-P1, DI-P2, DIV-P3, DIV-P4 and DIV-
P5 (lanes 10, 11, 14, 15 and 16, respectively), and 5 mg of DIV-P1, DIV-P2 (lanes 12
and 13, respectively), were analysed on a 10-20% (w/v) Tris-tricine peptide gel
(BioRad, CA, USA). Proteins were visualised by Coomassie Brilliant Blue staining.
Selected protein molecular mass standards (lanes 1, 9 and 17) are indicated.
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at 600.13 MHz on a Bruker Avance 600 MHz instrument equipped
with an UltraShield Plus magnet and a triple resonance cryoprobe
with gradient unit [39]. The 2D NMR experiments were performed
at 300 K without spinning with mixing times of 110 ms for the
TOCSY experiments and 250 ms for the NOESY experiments,
respectively (Fig. 1).
2.8. Co-culture assay
The co-culture assay has been described in detail earlier
[40]. Brieﬂy, green ﬂuorescent protein (GFP)-expressing HUVECs
and pulmonary artery SMCs were seeded simultaneously and
cultured in EGM-2 cell medium (Lonza, Basel, Basel, Switzerland)
for at least 72 h to ensure the formation of a stable network. The
cells (5  104 SMCs and 10  103HUVECs) were grown in a 96-well
plate with 200 ml medium. When seeded simultaneously, an
autonomous angiogenic programme is initiated that results in
neovascular-like network formation. The peptides were added to
the seeded co-cultures after 2 h. Following a 72 h treatment,
networks were imaged by ﬂuorescence microscopy.
2.9. Microscopy and image analysis
A BD Pathway 855 bioimaging system (BD Biosciences) was
used for automated quantitative analysis of the co-cultures in the
wells. Statistical analysis of the acquired images was carried out
with BD Image Data Explorer software. Images were acquired as
2  2 montages using a 10x lens. In particular, the branching and
tube network formation was followed by automated high-
throughput imaging of live cells using the AttoVision v1.6.1
programme that makes a 1-pixel wide representation of the
network by drawing a line through the middle of all the cellular
‘‘tubes’’ of the cellular network of the GFP-expressing ECs and the
parameter ‘‘tube total length’’ was used throughout all the
analyses. All data are representative of at least three independent
experiments. The results are expressed as the mean ( SEM) from
multiple (at least three) experiments. Statistical signiﬁcance was
determined using the two-tailed Student’s t-test and p-values <0.05
were considered as signiﬁcant.
3. Results
3.1. Design and puriﬁcation of the peptides
Seven different peptides (P) of bovine AnxA2 were designed
(Fig. 2A and B) and expressed as C-terminal fusion peptides,
coupled to maltose binding protein (MBP) to increase their
stability and solubility during expression and puriﬁcation. As
indicated in Fig. 2A, the peptides vary in length from 29 to
44 amino acids. The peptides P1 and P2 are based on the wt AnxA2-
DI (DI-P1 and DI-P2) or wt AnxA2-DIV (DIV-P1 and DIV-P2)
sequences harbouring helices A-B and D-E, respectively. The last
three peptides, namely DIV-P3, DIV-P4 and DIV-P5 are based on the
mutated DIV-sequence harbouring helices A-B, D-E and C-D-E,
respectively. Consequently, DIV-P1 and DIV-P3 as well as DIV-P2
and DIV-P4 are corresponding peptides, only differing in one or a
few amino acids. The mutations introduced into AnxA2-DIV to
render it more soluble are indicated in red letters (Fig. 2A) and
include Y269S, F270Y, V293S and V298S in DIV-P3 [33]. Peptides
DIV-P4 and DIV-P5 harbour the Y333S mutation. With the exception
of DIV-P5, each peptide was designed to harbour two anti-parallel
a-helices of the full-length (FL) protein to increase folding and
stability when separated from its fusion partner (MBP). DIV-P5
contains the same sequence as DIV-P4, but is extended to include
the putative plasminogen/plasmin binding site [19]. Thus, it islonger than the other peptides (Fig. 2). Two anti-parallel a-helices
often stabilise each other mainly through salt bridge formation and
hydrophobic interactions [42]. Close examination of the crystal
structure of bovine AnxA2 (PDB ID: 4X9P) and lower resolution
structures of human AnxA2 [32,43] shows that only peptide DI-P2
appears to be stabilised by a salt bridge between Lys88 in helix D
and Glu96 in helix E in the FL AnxA2 structure (Fig. 2A, underlined).
However, this could not be conﬁrmed by NMR (results not shown).
Helices A and B present in DI-P1, helix D in DI-P2, helix A in DIV-P1
and DIV-P3, helices D and E in DIV-P2 and DIV-P4 as well as helices C,
D and E in DIV-P5 are partly exposed in the FL AnxA2 protein
(Fig. 2B).
The His-MBP-fusion peptides could be puriﬁed in a soluble
state, either as truly soluble molecules or present in soluble
inclusion bodies due to their fusion with MBP [44] (Fig. 3A).
However, in order to merit further investigation for a possible
therapeutic use, it is crucial that the peptides themselves are
soluble upon cleavage from the fusion partner. We were able to
purify all seven AnxA2 peptides (Fig. 3B), however, it appears that
DIV-P3 has undergone partial proteolytic degradation, most likely
in the host bacteria (Fig. 3B, lane 14). Apparently, DIV-P2, DIV-P4
and DIV-P5 formed a minor proportion of dimers as indicated by
analysis in 10–20% Tris-tricine gels (Fig. 3B, lanes 13, 15 and 16,
respectively). It appeared that DIV-P5 is more prone to cleavage
with time (Fig. 3B, lane 16), most likely affecting the most N-
terminal helix C, since this is not stabilised by interaction with
another anti-parallel helix. Furthermore, it is possible that this
extra cleavage site in DIV-P5 is identical to the site cleaved by a
plasmin-like protease between Lys307 and Arg308 (Lys308 in
bovine AnxA2) [19], which is immediately preceding the DIV-P4
region (Fig. 2A) producing a cleavage product (Fig. 3B, lane 16),
with a size similar to that of DIV-P4 (Fig. 3B, lane 15).
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The aggregation tendencies of the AnxA2 peptides were
measured by light scattering assays 1 h before and 2 h after the
cleavage of the MBP fusion partner by the TEV protease (Fig. 4). The
assays were performed at 4 8C. Furthermore, when performed for
DI-P2 at 37 8C, similar results were obtained (results not shown). An
increase in the absorbance at 350 nm is a quantitative measurement
of protein aggregation with no contribution from the absorbance of
aromatic amino acids [45]. Also, it should be noted that the addition
of the TEV protease results in an apparent increase in absorbance at
approximately 60 min (Fig. 4), due to the opening of the lid of the
instrument. The light scattering measurements of the TEV protease
alone indicated no aggregation tendency (results not shown).Fig. 4. Aggregation tendencies of the AnxA2 peptides before and after cleavage from His-
AnxA2 peptides (1 mg/ml) measured at 350 nm (4 8C) are expressed as DA350 by subtrac
ratio) is indicated by arrowheads. The aggregation tendencies of DI-P1, DI-P2, DIV-P1, DIV-
indicates the degree of cleavage of the MBP fusion peptides after 2 h incubation with TE
DIV-P4 and DIV-P5 in lanes 1, 2, 3, 4, 5, 6 and 7, respectively. His-MBP-AnxA2 fusion pe
Coomassie Brilliant Blue staining.DI-P2, DIV-P2, DIV-P4 and DIV-P5 demonstrate a slight initial
tendency to aggregate when fused to MBP (Fig. 4B, D, F and G,
0-20 min), whereas none of the cleaved peptides appear to
aggregate at the concentrations used in the assays (1 mg/ml)
(Fig. 4). In order to determine the efﬁciency of TEV cleavage of the
peptides, samples taken directly from the cuvette at the end of the
light scattering assays (after 3 h) were subjected to SDS-PAGE and
Coomassie Brilliant Blue staining. The cleavage of the fusion
peptides by the TEV protease was partial (Fig. 4H) during the time
of measurement, but resulted in sufﬁcient free peptides to enable
the measurement of their aggregation tendencies. The uncleaved
fusion peptides (46–51 kDa), as well as cleaved MBP (43 kDa) are
visible by SDS-PAGE (Fig. 4H) while the peptides are too small to be
seen on a 10% SDS-PAGE. In conclusion, none of the cleaved AnxA2MBP, followed in real-time by light scattering. The changes in light scattering of the
ting background (20 mM Tris buffer; pH 8). The time of addition of TEV (1:50 molar
P2, DIV-P3, DIV-P4 and DIV-P5 are shown in A, B, C, D, E, F and G, respectively. Panel H
V at the end of the light scattering assays with DI-P1, DI-P2, DIV-P1, DIV-P2, DIV-P3,
ptides, His-MBP and peptides were separated by 10% SDS-PAGE and visualised by
Fig. 5. Far-UV CD spectra of the AnxA2 peptides at 20 8C. The far-UV CD spectra were recorded for (A) (50-120 mM) DI-P1 and DI-P2 in Tris buffer (pH 8) or (B) 50% TFE/Tris
buffer (pH 8). Similarly, the far-UV CD spectra were recorded for (70–170 mM) (C+D) DIV-P1 and DIV-P2 and (E and F) DIV-P3 - DIV-P5 in (C+E) Tris buffer (pH 8) or (D+F) 50%
TFE/Tris buffer (pH 8), respectively, as indicated. Spectra were background corrected and the observed optical activity is expressed as the mean residue molar ellipticity
[u]MRW (deg cm2 dmol1).
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duration of the light scattering assays (Fig. 4).
3.3. Secondary structure and stability of the AnxA2 peptides
The AnxA2 peptides were subjected to far-UV CD analysis to
elucidate their secondary structures both in an aqueous buffer
(20 mM Tris of pH 8) (Fig. 5A, C and E) and in 50% TFE/Tris buffer of
pH 8 (Fig. 5B, D and F). DIV-P1, DIV-P2, DIV-P3 and DIV-P4 appear to beFig. 6. CD-monitored thermal disruption of a-helicity of the AnxA2 peptides (range 10–70
(A, C and E) Tris buffer (pH 8) or (B, D and F) 50% TFE/Tris buffer. The thermal transitions w
Tris buffer (pH 8). Similarly, the far-UV CD spectra were recorded for (70-170 mM) (C) DIV
buffer (pH 8), respectively. The observed optical activity is expressed as the mean residue
(Tm) were determined from the ﬁrst derivative of the curve.relatively unstructured in 20 mM Tris (pH 8) buffer (Fig. 5C and E),
but with a certain degree ofa-helical content. By contrast, DI-P2, and
DIV-P5, display a structural conformation in aqueous solution
(Fig. 5A and E) with spectra that are characteristic of a predomi-
nantly a-helical structure with a double minima at 222 and 208 nm
and a maximum band around 190-195 nm. By far, DI-P2 appears to
be the most folded peptide of these two peptides. The strong
negative band at 198 nm suggests that DI-P1 (Fig. 5A) exists mainly
as a random coil structure in Tris buffer (pH 8). 8C). The change in ellipticity at 222 nm was measured at a heating rate of 40 8C/h in
ere recorded for (50-120 mM) (A) DI-P1 and DI-P2 in Tris buffer (pH 8) or (B) 50% TFE/
-P1 and DIV-P2 and (D) DIV-P3 - DIV-P5 in Tris buffer (pH 8) or (E and F) 50% TFE/Tris
 molar ellipticity [u]MRW (deg cm2 dmol1). The apparent transition temperatures
Fig. 7. CSI plot. Chemical shift differences (ppm) of the a-protons between the
experimental values and those for residues in a random coil for the peptide AnxA2
DI-P2 in (A) aqueous solution (H2O-D2O 9:1; v/v) at pH 3 and in (B) 50% aqueous
TFE-D2O at pH 3 at 300 K.
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thermal unfolding transitions (10-70 8C) were analysed by
monitoring the molar ellipticity at 222 nm in Tris buffer, pH 8
(Fig. 6A,C and E) and 50% TFE/Tris buffer (Fig. 6B, D and F). AnxA2-
DI-P2, but not DI-P1, exhibits a co-operative unfolding temperature
transition in Tris buffer, pH 8 (Fig. 6A) with a midpoint melting
temperature Tm of 54  1 8C, while in 50% TFE neither of the two
AnxA2-DI peptides show this behaviour (Fig. 6B) as the thermal
transition measurements indicate no clear melting temperatures.
Thus, the a-helical structure of the two AnxA2-DI peptides appeared
to be unstable in 50% TFE at higher temperatures (Fig. 6B).
All the AnxA2 peptides derived from domain IV exhibit a certain
degree of co-operative thermal unfolding transition in Tris buffer,
pH 8, except DIV-P5 (Fig. 6C and E). In each case, the co-operative
transitions have Tm’s of 55  2 8C. The initial linear part of the
thermal transition of these peptides (except DIV-P5) may correspond
to changes in their helicity that occur before the onset of the
cooperative unfolding. Except for DIV-P5, all AnxA2 peptides appear to
be stable in aqueous buffer until about 50 8C, as indicated by the
initial linear part of the CD thermal transition curves. They did not
exhibit this behaviour in 50% TFE solvent (Fig. 6B, D and F), suggesting
that the induced a-helical conformation of most of the AnxA2
peptides in 50% TFE solvent is not reﬂected in the stability of their
secondary structure in the same solvent.
3.4. Secondary structure of AnxA2-DI-P2 peptide
To obtain further structural information about the most folded
of the AnxA2 peptides, DI-P2, NMR spectra were obtained of the
peptide in H2O-D2O (9:1) and H2O-TFE (1:1). It has been shown
experimentally that a-proton chemical shifts greater than 0.1 ppm
relative to the random coil values are qualitative indicators of
protein secondary structure. A minimum of four adjacent residues
with an upﬁeld shift are indicative of an a-helix, whereas b-sheets
require a minimum of three residues with downﬁeld shifts
[46]. After spectral assignment, chemical shift index (CSI) plots
were made (Fig. 7) to indicate the location of the a-helical
structure. The peptide is structured (a-helical) both in aqueous
solution and in a more hydrophobic environment (H2O-TFE). The
localisation of structure appears to be the same in both cases
(Fig. 7), which is in agreement with the corresponding CD
spectra of DI-P2 (Fig. 5). The CD spectra of peptide DI-P2 indicate
relatively similar proportions of a-helical structure of the
peptide both in aqueous and H2O-TFE solution (Fig. 5). However,
the CSI plots showed that the a-helical structure is best deﬁned
when the peptide is present in hydrophobic environment (Fig. 7;
Tables 2 and 3). This may be accounted for by the fact that CD
spectroscopy is rather indicative with respect to determination of
exact proportions of a-helical structure when compared with NMR
spectroscopy, which provides structural information at atomic
resolution. The positive chemical shift deviation of Ha of G15 could
indicate that this residue acts as a helix breaker. However, the
crosspeaks at d 4.27/8.50 (Ha S14/HN L17), d 4.00/8.50 (Ha G15/
HN L17) d 8.34/8.23 (HN S14/HN G15), d 8.83/8.23 (HN L13/HN
G15), d 8.34/8.21 (HN S14/HN H16) and d 8.23/8.50 (HN G15/HN
L17) observed in the NMR spectra of DI-P2 recorded in TFE-H2O,
typical for peptides with a-helical structure, support the presence
of a continuous a-helix, in which G15 is incorporated (Tables 3A
and B).
3.5. DI-P2 potently inhibits the formation of a vascular-like network in
the co-culture system
To identify the regions of domains I and IV of AnxA2 containing
the important secondary structure (or site) that mediate their anti-
angiogenic effect, AnxA2 peptides (15 mM) were analysed for theirpotential inhibitory effects on capillary-like network formation in
the co-culture system (Fig. 8). Notably, only DI-P2 inhibited
strongly the formation of a network (Fig. 8D), diminishing the tube
total length value by approximately 60  10% (Fig. 8J). Furthermore,
in its presence the cells became more rounded in shape as compared
to the elongated control cells (Fig. 8A). Similar inhibition on network
formation and effect on cell morphology were observed in the
presence of PTK787, an inhibitor of the VEGF receptor-2 (VEGFR-2)
[47] (Fig. 8B and J). The other AnxA2 peptides inhibit network
formation only slightly at this concentration, except for DIV-P5, which
inhibits the process by approximately 20-30% (Fig. 8I and J).
Investigation of the dose-response effect of DI-P2, the most potent
anti-angiogenic peptide, showed that increasing the peptide concen-
tration from 7.5 mM to 30 mM increased the inhibition of network
formation from 20% to 60% (10%) (Fig. 9E), indicating a clear dose–
response relationship. However, none of the AnxA2 peptides were
able to disintegrate an already formed capillary-like network (Fig. 10).
4. Discussion
4.1. Puriﬁcation and characterisation of the AnxA2 peptides
AnxA2 plays a key role in angiogenesis and is therefore an
attractive target for cancer therapy [48]. Silencing of AnxA2
inhibits tumour growth, migration and thus invasion of hepatoma
cells [49]. Since it is a multifunctional protein, knocking down its
mRNA by siRNA or RNAi treatment may severely affect its other
cellular functions. Furthermore, antibody-based therapy targeting
extracellular AnxA2 may also have other major drawbacks in
addition, such as high production costs and low efﬁciency of drug
Table 3A
1H chemical shifts of ANX-A2-DI-P2 in H2O-D2O (9:1; v/v) at 298 K.
HN Ha Hb Hg Hd He NH2 Ar H
M1 4.08 2.11 2.54 2.06
K2 8.69 4.29 1.73 1.36 1.63 2.93 7.48
K3 8.46 4.22 1.71 1.36 1.64 2.93 7.48
E4 8.50 4.29 1.99/1.88 2.32
L5 8.30 4.28
A6 8.33 4.22 1.35
S7 8.19 4.28 3.81
A8 8.19 4.28 1.35
L9 8.01 4.23 1.59 1.53 0.86/0.82
K10 8.19 4.23 1.79 1.62 1.72 2.93 7.48
S11 8.16 4.34 3.81
A12 8.28 4.25 1.35
L13 8.09 4.28 1.59 1.59 0.85
S14 8.10 4.34 3.82
G15 8.31 3.88
H16 8.28 4.64 3.22/3.11 8.55/7.21
L17 8.29 4.27 1.58 1.51 0.86/0.81
E18 8.41 4.34 2.04/1.93 2.37
T19 8.11 4.20 4.09 1.13
V20 8.09 4.01 1.98 0.85
I21 8.21 4.05 1.79 1.42/1.11
0.82/0.77
L22 8.31 4.25 1.63 1.58 0.87/0.82
G23 8.26 3.85
L24 7.91 4.26 1.55 1.55 0.83
L25 8.11 4.29
K26 8.28 4.33 1.81 1.63 1.72 2.94 7.48
T27 7.99 4.25 4.18 1.14
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[50]. Therefore, peptides are attractive as potential therapeutic
agents and in fact have been used with success as anti-angiogenic
drugs [51], although their usefulness as therapeutic agents is
limited by their aggregation tendency, which may cause reduced
stability, loss of efﬁcacy, the onset of unwanted immunogenic
effects and false positive results due to nonspeciﬁc inhibition of
receptors. Therefore, the stability of a given peptide as well as itsTable 3B
1H chemical shifts of AnxA2-DI-P2 in TFE-H2O (1:1; v/v) at 300 K.
HN Ha Hb Hg 
M1 4.19 2.28/2.21 2.72/2.6
K2 8.49 4.11 2.08 
K3 8.83 4.13 1.92 1.52 
E4 9.40 4.16 2.40/2.10 2.60
L5 7.54 4.32 1.86 1.71 
A6 8.09 4.12 1.53
S7 8.12 4.25 4.07/4.02
A8 7.94 4.23 1.62
L9 8.50 4.18 1.87 1.69 
K10 8.30 4.05 2.03 1.66/1.5
S11 8.21 4.28 4.17/4.05
A12 8.35 4.27 1.62
L13 8.83 4.23 1.71 1.52 
S14 8.34 4.27 4.13/4.06
G15 8.23 4.00
H16 8.21 4.56 3.48/3.43 
L17 8.50 4.11 1.88 1.79 
E18 8.51 3.99 2.31/2.20 2.64/2.4
T19 7.71 3.98 4.41 1.35
V20 7.74 3.72 2.34 0.96
I21 8.32 3.72 1.97 1.23/0.9
L22 8.41 4.14 1.90 1.57 
G23 7.90 3.95/3.87
L24 8.26 4.22 2.09/1.89 1.60 
L25 8.51 4.18 1.86 1.69 
K26 8.13 4.25 2.03 1.66/1.5
T27 7.81 4.28 4.39 1.36 structure needs to be studied and elucidated before concluding
regarding its efﬁcacy as a putative drug. It has been possible to
obtain two of the domains of AnxA2 in a soluble form: Domain I
(including 9 amino acids of the N-terminal tail), which possesses
autonomous folding capacity [52], and a mutant domain IV which
is capable of partial folding after the hydrophobic amino acids
involved in interfacial contacts with the other domains have been
mutated to hydrophilic ones [33]. As the design of the AnxA2Hd He NH2 Ar H
2 2.13
3.07 7.62
1.76 3.00 7.62
1.00
0.91
0 1.75 3.00 7.62
0.94
8.55
7.25
0.97
9
6/0.86
0.93
0.91
0.91
9 1.75 3.03 7.62
7.33/6.99
Fig. 8. Effect of the AnxA2 peptides on in vitro formation of a capillary-like network in co-cultures. Co-cultures of SMCs and GFP-expressing HUVECs were (A) untreated, or
treated with (B) 100 nM PTK787, (C) 15 mM of DI-P1, (D) DI-P2, (E) DIV-P1, (F) DIV-P2, (G) DIV-P3, (H) DIV-P4, or (I) DIV-P5 2 h after seeding. After 72 h incubation, images were
taken at 10x magniﬁcation. The analysis of the tube total length (J) is expressed as percentage relative to the untreated control network (100%) (A), using the Attovision and BD
Image Data Explorer programmes. Results (J) represent the mean  SEM of 3 independent experiments. Statistical signiﬁcance was determined by the two-tailed Student’s t-test
(*P < 0.05).
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containing regions that in the FL protein harbour two anti-parallel
a-helices, it was of importance to determine if the design was
successful in promoting a-helical secondary structure. Normally,
the AnxA2 protein as well as its domains I and IV were stored in Tris
buffer (pH 8), which is not ideal for CD measurements due to its
high absorbance in the lower nm region. However, Tris buffer was
preferred over phosphate buffer due to the inhibitory effect of the
latter on network formation in the co-culture system (results notshown). Thus, due to UV absorption of the Tris buffer, accurate
percentage calculations of secondary structure cannot be per-
formed, while spectral comparisons are possible. It was also of
interest to investigate whether the mutations initially introduced
into the variant form of AnxA2-DIV (see above) would stabilise an
a-helical structure of the peptides in an aqueous environment
(Fig. 5C and E, compare DIV-P1 with DIV-P3 and DIV-P2 with DIV-P4).
Apparently, the mutations introduced in DIV-P3 increased its
a-helicity in the Tris buffer when compared to DIV-P1 while the
Fig. 9. The dose–response effect of DI-P2 on in vitro formation of a capillary-like
network. Co-cultures of SMCs and GFP-expressing HUVECs were (A) untreated, or
treated with (B) 7.5 mM, (C) 15 mM, or (D) 30 mM DI-P2 2 h after seeding. After 72 h
incubation, images were taken at 10x magniﬁcation. The analysis of the tube total
length (E) was performed as described in the legend to Fig. 8.
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DIV-P2 (Fig. 5, compare C and E).
TFE stabilises a-helical structures via several mechanisms
[53]. One possible mechanism is that TFE aggregates around the
peptide forming a matrix that partly excludes water and thus
mimics a hydrophobic environment. The matrix promotes the
formation of local interactions and hence the formation ofsecondary structure [54]. In the presence of the a-helix inducing
solvent, 50% TFE, all AnxA2 peptides gain various degrees of
secondary a-helical structure, except DI-P2 (Fig. 5, compare A, C
and E with B, D and F). This implies that the AnxA2 peptides have a
tendency to fold when present in a hydrophobic environment
suggesting that they adopt a more folded conformation when
associated with lipids in membranes.
The biophysical characterisations of the AnxA2 peptides
indicate that DI-P2 is the only a-helical peptide with a relatively
high stability in aqueous solution. The pI values of the different
AnxA2 peptides as determined by ExPASY [55] do not appear to
affect their conformation since some are acidic (DI-P1, DIV-P2 and
DIV-P4 have pI values of 4.99, 4.78 and 4.78, respectively) while
others are basic (DI-P2, DIV-P1, DIV-P3 and DIV-P2 have pI values of
9.40, 9.69, 9.69 and 9.30, respectively). The NMR data conﬁrmed
that peptide DI-P2 is structured (a-helical) both in aqueous
solution and in a more hydrophobic environment (H2O-TFE). The
localisation of structure appears to be the same in both cases
(Fig. 7), although the CSI plots showed that the a-helical structure
is best deﬁned when the peptide is present in hydrophobic
environment (Fig. 7).
4.2. DI-P2 as a candidate for an anti-angiogenic therapeutic agent
Previously, we showed that domains I and IV of AnxA2 in low
concentration (15 mM) strongly inhibit the formation of a
capillary-like network in the co-culture system [29]. Activation
of plasminogen did not appear to be important, while the
disruption of the VE-cadherin-mediated contacts between ECs
appeared to be an essential part of this effect [29]. In the present
study, DI-P2 was the only peptide that strongly inhibited the
formation of a network of HUVECs grown on SMCs (Figs. 8 and 9). It
should be noted that the inhibition of network formation appears
to be less pronounced in Fig. 8J than in Fig. 9E, most likely due to
the use of a slightly less dense population of HUVECs and/or lower
degree of network formation (Fig. 9A). The inhibitory effects of the
DI-P2 peptide were consistent from experiment to experiment
with the normal variation of displaying 10%. Network formation
in the co-culture system has been described in detail previously
[40]. HUVECs transfected with either GFP or RFP are able to form a
network on conﬂuent SMCs, but not when cultured alone as
monolayers, since network formation is dependent on SMC-derived
VEGF [40]. The capillary-like network of HUVECs forms a lumen as
evidenced by the luminal concentration of exogenously added TRITC-
dextran, see Fig. 1 in [40]. The capillary-like tubules of ECs formed in
vitro and the resulting vascular-like network possess many of the
features observed in vivo, including deposition of basement
membrane, formation of adherens junctions and lumen as well as
the establishment of direct contacts between the two cell types
[40]. Therefore, it is ideal as an initial imaging screening method. In
contrast to domains I and IV of AnxA2 [29], none of the AnxA2
peptides were able to disrupt a pre-formed network in the co-culture
system to a signiﬁcant extent (Fig. 10). One possible explanation is
that in the pre-formed vascular-like network, the mature, stable
adherence junctions established between ECs, are not easily
disrupted by small peptides. Alternatively, due to a putative lower
afﬁnity of the peptides compared to the domains, they may be
inefﬁcient in competing for binding with a ligand of endogenous
AnxA2. One major difference between the formation of a network and
the maintenance of a stable network in the co-culture system is the
VEGF dependency. HUVECs in the co-culture system are totally
dependent on SMC-derived VEGF to form a network, which cannot be
replaced by exogenously added, soluble VEGF or other growth factors
such as FGF. In contrast, when the network has been formed, the
HUVECs become largely independent of this SMC-derived VEGF
production [41]. Thus, it is possible that the peptide, DI-P2, is able to
Fig. 10. The effect of the AnxA2 peptides on the integrity of pre-formed mature capillary-like networks. Co-cultures of SMCs and GFP-expressing HUVECs with a pre-formed
network were (A) untreated, or treated with (B) 100 nM PTK787, 15 mM of (C) DI-P1, (D) DI-P2, (E) DIV-P1, (F) DIV-P2, (G) DIV-P3, (H) DIV-P4, or (I) DIV-P5. After 72 h incubation,
images were taken at 10x magniﬁcation. The analysis of the tube total length (E) was performed as described in the legend to Fig. 8.
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reported for the FL AnxA2 protein during ischemia-induced retinal
neoangiogenesis [56]. Therefore, it could be interesting to develop
this peptide further for use in anti-angiogenic therapy.
AnxA2 may be involved in angiogenesis at several levels. It may
(i) act as a co-receptor for tPA and plasminogen to generate
plasmin [57], (ii) regulate the ‘‘locking’’ of VE-cadherin-based
complex to lipid rafts and the actin cytoskeleton and/or (iii)
modulate actin dynamics. A hexapeptide, LCKLSL, containing the
tPA-binding site in the N-terminus of AnxA2, competes withendogenous AnxA2 and thus inhibits the generation of plasmin
[58]. Another synthetic 36 amino acid long peptide derived from
the venom of a scorpion (TM601) also inhibits the activation of
plasmin by binding to AnxA2 [59]. However, our previous ﬁndings
provide evidence that the anti-angiogenic effects of domains I and
IV of AnxA2 are not due to their inhibitory effects on the activation
of plasminogen [29].
In conclusion, a fast and relatively inexpensive strategy was
adopted to express and purify AnxA2 peptides fused to MBP using
bacteria. It is possible that MBP improves the solubility of the
A.M. Raddum et al. / Biochemical Pharmacology 95 (2015) 1–1514peptides. Real time light scattering measurements were performed
to provide estimates of the aggregation tendencies of the cleaved
AnxA2 peptides. Based on the biophysical characterisations (far-UV
CD and thermal transition measurements) of the AnxA2 peptides, it
can be proposed that the inhibitory effect of DI-P2 on the formation
of a VEGF-dependent capillary-like network in the co-culture
system (hydrophilic environment) is due to its a-helical conforma-
tional structure corresponding to those found in the FL native AnxA2
protein. The NMR data conﬁrmed that the DI-P2 peptide is
structured (a-helical) in aqueous solution. Thus, the anti-angiogenic
effect of DI-P2 in the co-culture system does not appear to involve its
unspeciﬁc binding to lipids, but rather its interference with AnxA2-
mediated effects that are VEGF-dependent and based on its
competition with endogenous extracellular AnxA2.
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